Sample Submission Guidelines
Decoding 3D Complexity: The Need for Specialized Multi-Omics
Patient-derived organoids sit at the critical intersection between hyper-simplified 2D cell cultures and complex, expensive, and ethically constrained in vivo animal models. Because they are grown in 3D matrices, they retain the spatial architecture, cellular heterogeneity, and physiological responses of their source tissues. However, this profound biological authenticity introduces severe analytical bottlenecks. A 3D organoid is not a uniform mass of identical cells; it is a complex, miniature ecosystem. It contains active stem cell niches, fully differentiated progeny, apoptotic/necrotic cores due to nutrient gradients, and varying metabolic states depending on physical location within the Matrigel dome.
Standard bulk sequencing methodologies developed for 2D cell lines often fail to capture this nuance. Averaging the expression profiles of millions of cells completely masks the critical subclonal populations—such as a rare, pre-existing drug-resistant cancer clone or a transient developmental progenitor—that drive the very phenotype you are trying to study. Furthermore, the unique physical properties of organoids require highly specialized extraction and library preparation protocols that standard commercial sequencing pipelines simply cannot handle.
To unlock the full potential of your 3D models, CD Genomics offers a tiered suite of organoid sequencing and analysis services. By comparing the specific advantages, input requirements, QC metrics, and bioinformatic deliverables of each service, you can precisely match your biological question to the optimal sequencing strategy, ensuring maximal data yield and conserving precious biobank samples.
Sequencing Modality Selection Guide: Matching Question to Technology
Selecting the right sequencing service is not about choosing the newest or most expensive technology; it is about aligning the assay's resolution with your specific scientific hypothesis. Below is our strategic routing guide.
1. Bulk RNA Sequencing (RNA-seq)
Best For: Cost-effective global expression profiling, pathway enrichment analysis (control versus treated paradigms), and initial biobank validation.
The Limitation: It averages the expression of all cells, completely masking the spatial and cellular heterogeneity inherent to 3D organoids. A rare cell type comprising 1% of the organoid will be lost in the background noise.
Routing: Discover more at our Organoid Sequencing Services.
2. Single-Cell & Single-Nucleus RNA Sequencing (sc/snRNA-seq)
Best For: Dissecting cellular heterogeneity, identifying rare stem cell niches, mapping developmental trajectories (pseudotime), and analyzing complex co-culture models (e.g., patient-derived tumor organoids co-cultured with autologous T-cells).
The Advantage: We utilize both 10x Genomics Chromium droplet microfluidics and optimized single-nucleus (snRNA-seq) protocols. snRNA-seq is particularly crucial for large, dense, or heavily fibrotic organoids that cannot be enzymatically dissociated into live single cells without inducing massive transcriptional stress (which artificially inflates stress-response genes like FOS and JUN). snRNA-seq extracts only the nuclei from flash-frozen tissue, bypassing live-cell dissociation bias entirely.
Routing: Discover more at our Organoid Sequencing Services.
3. Spatial Transcriptomics (Spatial RNA-seq)
Best For: Mapping gene expression directly onto the preserved 3D physical architecture of the organoid slice.
The Advantage: While scRNA-seq requires total tissue dissociation (destroying all spatial context in the process), Spatial Transcriptomics (utilizing cutting-edge platforms like 10x Visium or BGI Stereo-seq) allows researchers to see exactly where specific genes are active. This is absolutely critical for analyzing the invasive front of a tumor organoid, studying the exact boundary of nutrient-gradient necrosis, or mapping the physical, receptor-ligand interactions between an organoid and surrounding stromal or immune cells in a 3D co-culture model. It bridges the gap between histology and transcriptomics.
4. Organoid Whole Exome Sequencing (WES)
Best For: Validating the genomic fidelity and mutational landscape of patient-derived models.
The Advantage: It is imperative to prove that your organoid actually retains the specific somatic driver mutations (e.g., KRAS, TP53, PIK3CA) present in the original patient's primary tumor. WES maps clonal evolution and calculates mutational burdens over continuous in vitro passaging, ensuring your model hasn't drifted into irrelevance.
Routing: Read the detailed Triad-comparison strategy at our Organoid Whole Exome Sequencing Services.
5. Advanced Epigenomic & Pharmacological Profiling
For questions moving beyond baseline genomics and transcriptomics, we route samples to our highly specialized pipelines:
- High-Throughput Drug Screening: If you need to test hundreds of drugs, standard RNA-seq is too expensive. Route to Organoid Drug Response Transcriptomics (DRUG-seq) for massive 384-well multiplexing, allowing transcriptomic readouts for high-throughput screening instead of simple cell-death assays.
- Chromatin & Enhancer Mapping: If your organoid is differentiating incorrectly without DNA mutations, the epigenome is responsible. Route to Organoid Epigenetic Profiling (CUT&Tag / scATAC-seq) to uncover the regulatory switches and open chromatin regions driving cellular behavior using extremely low cell inputs.
- Dynamic RNA Turnover: Route to Organoid RNA Stability Analysis (SLAM-seq) for immediate-early kinetic responses, allowing you to measure exact mRNA degradation half-lives within minutes of applying a targeted therapy.
Sample Adaptability & Stringent QC Metrics
The quality of your sequencing data is inextricably linked to sample preparation. Organoids embedded in proteinaceous extracellular matrices (ECM) like Matrigel or Cultrex present severe biochemical challenges, including enzymatic inhibition during library prep and aggressive RNA degradation. We employ customized extraction protocols, gated by strict Quality Control (QC) metrics tailored to the specific sensitivities of each sequencing technology.
| Sequencing Technology | Ideal Sample State | Minimum Input Requirement | Critical QC Metrics & Thresholds |
|---|---|---|---|
| Bulk RNA-seq / WES | Snap-frozen pellet (Matrix-free) | RNA: >500 ng DNA: >500 ng |
RIN > 8.0 (RNA Integrity Number); DIN > 7.0 (DNA Integrity); OD260/280 ~2.0. Complete macroscopic and microscopic absence of Matrigel is mandatory to prevent downstream polymerase inhibition. |
| scRNA-seq | Live, single-cell suspension | >100,000 cells | Viability > 85% via dual-fluorescence staining; Cell clumping < 5%; Minimal ambient RNA (low background debris). Strict enzymatic timing must be observed to prevent artificial stress signatures. |
| snRNA-seq | Snap-frozen organoids (Flash frozen) | >50,000 cells | Nuclei integrity visually confirmed via Trypan Blue or DAPI staining under a microscope; minimal nuclear membrane blebbing; low cytoplasmic RNA contamination in the suspension. |
| Spatial Transcriptomics | OCT-embedded fresh frozen blocks or FFPE | Tissue block (≥ 2mm diameter) | RNA Quality Score (DV200 > 50% for FFPE samples); Precise cryosectioning thickness (typically exactly 10 µm) to avoid transcript diffusion and ensure uniform permeabilization. |
| CUT&Tag / ATAC-seq | Lightly crosslinked or native cell pellets | 10,000 – 100k cells | High cell/nuclei viability; extraordinarily strict cell counting is required to maintain the exact stoichiometric ratio of Tn5 transposase to chromatin during the tagmentation step. |
Comparative Sequencing and Analysis Workflows
While standard 2D cell line sequencing follows a highly generic path, 3D organoid sequencing requires bifurcated, highly specialized workflows from the moment of lysis to the final bioinformatic output.
1. Matrix Dissociation and Library Preparation
- Bulk RNA/DNA Extraction: The workflow focuses heavily on aggressive cold-lysis utilizing proprietary buffers to dissolve the ECM proteins completely without triggering endogenous RNAse activity. Libraries are then prepared using standard poly-A capture (for mRNA) or acoustic shearing followed by exome probe hybridization (for WES).
- Single-Cell Partitioning: This workflow requires gentle, temperature-controlled enzymatic dissociation (e.g., using TrypLE and DNase I) to liberate single cells while immediately halting metabolic activity. We then utilize 10x Genomics Chromium droplet microfluidics to partition individual cells into lipid droplets with uniquely barcoded Gel Beads-in-emulsion (GEMs), allowing massive parallel barcoding of the transcriptome.
- Spatial Transcriptomics Capture: Organoid blocks are sectioned directly onto spatially barcoded capture slides. The tissue is permeabilized in situ under highly optimized timeframes so that the mRNA diffuses directly downward and binds to the exact spatial coordinate barcode directly beneath it, preserving the X-Y coordinate of every transcript.
2. Specialized Bioinformatics Pipelines
- WES Pipeline: Emphasizes germline subtraction. We align reads to the hg38 reference genome and utilize ensemble variant callers (combining Mutect2, Strelka2, and VarScan) to isolate pure somatic variants. We then calculate Jaccard similarity indices against the patient's primary tumor sequencing data.
- sc/snRNA-seq Pipeline: A massive challenge in organoid scRNA-seq is the "soup" of ambient RNA released by dead cells in the organoid's necrotic core. Our workflow heavily utilizes decontamination algorithms (e.g., SoupX) to computationally remove this ambient background noise before performing dimensionality reduction (UMAP/t-SNE) and automated cell-type annotation using established organoid and primary tissue reference atlases.
- Spatial Pipeline: Merges high-resolution histological imaging (H&E or Immunofluorescence) with transcriptomic count matrices (using pipelines like 10x SpaceRanger). Because a single 55µm capture spot may contain 5-10 cells, this workflow requires complex spot-deconvolution algorithms (e.g., RCTD or Cell2location) to mathematically estimate the proportion of different sub-cell types existing within a single coordinate.
Comprehensive Deliverable Files
We understand that data is useless if it cannot be interpreted. CD Genomics does not just provide massive, impenetrable spreadsheets of raw reads; we deliver interactive, publication-ready formats designed for immediate exploration and downstream functional validation by your biological teams.
- Raw & Aligned Data: Highly cleaned, demultiplexed FASTQ files; Indexed BAM or CRAM files (ready for immediate genome browser visualization in IGV).
- Variant Files (For WES/Epigenetics): Extensively annotated VCFs integrated with clinical databases like ClinVar, COSMIC, and dbSNP; BED files detailing peak calls for ATAC-seq or CUT&Tag.
- Single-Cell & Spatial Objects: Fully processed and annotated
.rds(Seurat) or.h5ad(Scanpy) objects containing normalized matrices and metadata. For spatial transcriptomics, we provide proprietary.cloupefiles fully integrated with the H&E tissue images for intuitive, point-and-click exploration in the 10x Loupe Browser. - Publication-Ready Reports: Highly detailed PDF bioinformatics reports encompassing all QA/QC metrics, detailed methodology text for your manuscripts, custom data visualizations (Hierarchical Heatmaps, UMAPs, Spatial expression overlays, Venn diagrams), and advanced pathway enrichment analysis (GSEA, GO, KEGG).
References:
- Bock C, Boutros M, Camp JG, et al. The organoid revolution. Nature. 2022;602(7898):391-400.
- Marx V. A dream of single-cell spatial biology. Nature Methods. 2021;18(1):9-14.
- Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer. 2018;18(7):407-418.
- Boretto M, Cox B, Noben M, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nature Cell Biology. 2019;21(8):1041-1051.
- Vlachogiannis G, Hedayat S, Vasantharajan A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926.
For research use only. Not for use in diagnostic procedures, clinical decision-making, patient stratification, therapeutic selection, or clinical trials.
Illustrative Analysis Results
The following planned visuals explain common deliverable structures provided in our organoid multi-omics reports. They are illustrative examples demonstrating data formats, not actual patient data.
Spatial Transcriptomics: Expression Overlays
By mathematically overlaying gene expression count data directly onto the H&E image of the sectioned organoid, researchers can physically locate the hypoxic core (e.g., observing HIF1A or VEGFA overexpression in the center) versus the highly proliferative outer rim (e.g., MKI67 expression). In co-culture models, spatial overlays perfectly delineate the invasive boundaries between the tumor organoid mass and surrounding stroma. This profound structural context is entirely lost in bulk or single-cell sequencing.
scRNA-seq: Pseudotime Trajectory Mapping
Visualizing cellular state transitions. By applying trajectory inference algorithms (like Monocle3) to the single-cell expression data, we project how stem cells within the organoid gradually differentiate into mature, specialized lineages along a continuous temporal axis. This allows researchers to pinpoint the exact transcriptional checkpoints where differentiation stalls in disease models or where drug interventions force a lineage shift.
Genomic & Transcriptomic Integration
Multi-omic scatter plots that align the Variant Allele Frequency (VAF) calculated from Whole Exome Sequencing data with the global expression profiles derived from bulk RNA-seq data. This integrated visualization proves definitively that the dominant, proliferating subclone in your in vitro culture is both genetically aberrant and actively driving the malignant transcriptomic signature you are studying.
Case Studies: Multi-Omics in Action
Case Study 1: Dissecting Intestinal Stem Cell Dynamics via Integrated scRNA-seq and scATAC-seq
Background: Researchers studying inflammatory bowel disease (IBD) developed complex human intestinal organoids to model the rapid renewal process of the intestinal epithelium. However, they struggled to understand the epigenetic switches that force uncommitted stem cells to differentiate into mature enterocytes and goblet cells.
Methodology: CD Genomics performed parallel single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) on highly viable single-cell suspensions derived from the organoids at multiple differentiation time points.
Results: While the scRNA-seq data mapped the continuous developmental trajectory, the breakthrough came from the integrated scATAC-seq data. The analysis identified massive shifts in chromatin accessibility at specific enhancer regions before the corresponding lineage-defining genes were actively transcribed. The multi-omics map pinpointed a previously uncharacterized master transcription factor whose binding dictated the fate decision toward the goblet cell lineage.
Case Study 2: Spatial Transcriptomics on Tumor-Immune Co-Cultures
Background: An immuno-oncology lab developed a 3D co-culture model consisting of patient-derived melanoma organoids embedded in a matrix alongside autologous cytotoxic T-cells. They needed to understand why the T-cells failed to penetrate the core of the organoid mass.
Methodology: Instead of dissociating the model, the lab utilized our Spatial Transcriptomics service. The intact co-culture blocks were cryosectioned onto spatially barcoded arrays, capturing both the histology and the localized transcriptome.
Results: The spatial expression overlay revealed a distinct boundary layer. T-cells physically adjacent to the organoid periphery exhibited severe upregulation of exhaustion markers (PDCD1, LAG3), whereas the outer rim of the tumor organoid highly expressed immunosuppressive ligands (CD274/PD-L1). Crucially, the spatial map showed that this suppressive signature was highly localized to the physical interface, entirely explaining the lack of core penetration in a way that dissociated scRNA-seq could never have captured.
Case Study 3: High-Throughput Drug Repurposing using DRUG-seq
Background: A translational group possessed a biobank of 50 colorectal cancer organoids and aimed to screen a library of 1,200 FDA-approved compounds to identify repurposing candidates. Standard RNA-seq was cost-prohibitive for 60,000 total wells.
Methodology: The group utilized Organoid Drug Response Transcriptomics (DRUG-seq). Organoids in 384-well plates were treated, and early well-specific barcoding allowed massive pooling for high-throughput 3'-end counting.
Results: The dataset provided a distinct transcriptomic signature for every compound. Clustering revealed that three visually unrelated drugs all converged to heavily downregulate the Wnt/beta-catenin pathway. This profound transcriptional shift was entirely missed by standard cell-death assays, yielding three novel repurposing candidates.
Organoid Sequencing FAQs
1. I want to sequence my organoids but I don't know where to start. What is the baseline recommendation?
If you have just established a new organoid line and need basic validation, we strongly recommend pairing Organoid WES (to confirm the genetic identity matches the original patient tissue) with bulk RNA-seq (to confirm global expression profiles match the tissue of origin). Once the baseline fidelity is validated, you can scale up to high-resolution Single-Cell or Spatial applications.
2. Why should I use snRNA-seq instead of scRNA-seq for my organoids?
Standard scRNA-seq requires the organoid to be broken down into living single cells. Large, dense, or heavily fibrotic organoids often die during this harsh enzymatic dissociation, leading to biased sequencing of only the most robust cell types. Single-nucleus RNA-seq (snRNA-seq) extracts only the nuclei from flash-frozen tissue, bypassing the need for live cell dissociation and providing an unbiased transcriptomic profile of the entire organoid architecture.
3. What is the precise difference between Spatial Transcriptomics and Spatial Proteomics?
Spatial transcriptomics maps the expression of thousands of mRNA transcripts across the organoid slice simultaneously using spatially barcoded capture arrays. Spatial proteomics (multiplexed immunofluorescence) maps specific proteins using fluorophore-conjugated antibodies. Transcriptomics is unparalleled for unbiased, genome-wide discovery, while proteomics is superior for validating functional protein expression and delineating exact cellular boundaries.
4. Can you process FFPE organoid blocks for Spatial Transcriptomics?
Yes. While fresh-frozen (OCT-embedded) organoids yield the highest quality whole-transcriptome data, we utilize specialized probe-based spatial technologies to map whole transcriptomes from archival Formalin-Fixed Paraffin-Embedded (FFPE) organoid blocks, provided the RNA DV200 score meets our strict QC thresholds.
5. How does DRUG-seq differ from bulk RNA-seq in high-throughput screening?
Standard bulk RNA-seq sequences the entire length of the mRNA transcript at high depth, which is highly expensive and limits throughput. DRUG-seq is a specialized, multiplexed technique that only sequences a tiny tag at the 3' end of the mRNA. By barcoding the samples extremely early in the lysis process, we can pool thousands of wells together in a single sequencing run, achieving massive cost-efficiency.
6. How long does the analysis process take?
Turnaround time is highly project-dependent. It fluctuates based on sample volume, specific preparation requirements, the chosen sequencing modality, depth of sequencing, and the complexity of the bioinformatic integration required. Data is delivered securely via cloud download immediately once all quality control parameters and rigorous bioinformatic checks are met.